MedTrace Logo

Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis

NCT03706209 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2024-11-22

Study results available
· View outcomes & findings →

Summary

The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.

Conditions

Interventions

DRUG

MP1032

hard gelatin capsules containing 50mg MP1032 as active ingredient

DRUG

Placebo

hard gelatin capsules containing no active ingredient

Sponsors & Collaborators

  • Bioskin GmbH

    collaborator INDUSTRY

  • MetrioPharm AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2019-06-12
Completion
2019-06-12

Countries

  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706209 on ClinicalTrials.gov